Medicare

Publication Analyzes Clinical Efficacy of Deep TMS™ in Treating Different Brain Regions Associated with Major Depressive Disorder

Study Results Outline a Potential Path to More Personalized Medicine in Noninvasive Brain StimulationBURLINGTON, Mass. and JERUSALEM, Jan. 31, 2023...

NeuroMetrix® Announces Launch of DPNCheck® 2.0, its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy

Point-of-care technology helps healthcare providers rapidly identify at-risk patients DPNCheck 2.0 by NeuroMetrix This rapid point-of-care screening test provides accurate...

BrainsWay Announces Extended Private Insurance Coverage in Washington State for the Treatment of OCD and Depression Utilizing Deep TMS™

BURLINGTON, Mass. and JERUSALEM, Jan. 11, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...

Helius Medical Technologies, Inc. Announces Participation of Neurology Center of New England in its Therapeutic Experience Program

-- Fifth Center of Excellence added in multi-center, company-sponsored, open label observational interventional trial to evaluate the impact of subjects’...

Helius Launches UpScript Telehealth e-Commerce Site, Making it Easier for Americans with Multiple Sclerosis to Access Neurotech that can Improve their Ability to Walk

New Partnership with UpScript Provides Access to Care, Delivers PoNS Devices to DoorstepsNEWTOWN, Pa., Jan. 03, 2023 (GLOBE NEWSWIRE) --...

Adaptive Biotechnologies Highlights New Data Showcasing the Clinical Utility of clonoSEQ® MRD Testing in Patients with Blood Cancers at the 64th ASH Annual Meeting

Multiple presentations reinforce clonoSEQ’s ability to provide valuable insights for treatment surveillance and clinical decision-makingMore than 30 clonoSEQ-related abstracts to...

error: Content is protected !!